Khiron Life Sciences and Dayacann form joint venture

1 minute read
21 January 2019

On Jan. 21, 2019, Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) (Frankfurt: A2JMZC) announced that it had closed the previously announced MOU with Dayacann, holder of Chile's first and only medical cannabis cultivation license.

Dayacann is a joint venture entity established by Fundacion Daya and its Australian partner AusCann Group Holdings Ltd.

Khiron, with core operations in Colombia, is positioned to be the dominant integrated medical cannabis company in Latin America. This agreement expands on Khiron's multi jurisdiction cultivation strategy, securing access to cannabis cultivation for the company’s use in Chile, participation in clinical trials, and access to commercialize products to meet the needs of a market of 1.8 million patients across the country.

Gowling WLG advised Khiron with respect to this agreement with a team that included Peter Simeon, Marek Lorenc and Josh Rosen.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.